IL4 and gastric cancer: Overall, 54.8% of gastric cancer patients carried the IL-4 -590T SNP, which was significantly higher than that of H. pylori-positive asymptomatic controls (28.3%, P=0.02), which again recognized IL-4 -590 T carriers (CT and TT) at a moderately increased risk of gastric cancer [(OR=1.63, 95% CI=1.05-2.52), Fig. 2B).